Retrospective study analyzing the efficacy and toxicity of P-Gemox (Pegaspargase, Gemcitabine, Oxaliplatin) in the treatment of Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma (ENKTL)

Trial Profile

Retrospective study analyzing the efficacy and toxicity of P-Gemox (Pegaspargase, Gemcitabine, Oxaliplatin) in the treatment of Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma (ENKTL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Pegaspargase (Primary)
  • Indications T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top